Vasculitis & polymyalgia rheumatica
Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study
Authors' conclusion
Our preliminary data show that step-down therapy with mepolizumab to 100 mg/4 weeks was effective in maintaining systemic remission and reducing GC use in EGPA patients.
Study context
- Population
- Eosinophilic granulomatosis with polyangiitis (EGPA) patients treated with mepolizumab between April 2014 and December 2024, single centre12 (27%) stepped down
- Participants
- 45 patients
- Exposure
- Step-down from mepolizumab 300 mg/4 weeks to 100 mg/4 weeks after remission
- Step-downn = 12
- Outcome
- Maintenance of complete remission without glucocorticoids (GC) therapy after step-down
- Follow-up
- Median 27.5 months post-step-down
Methodological detailssingle-centre, real-life
- Single-centre
- Real-life
Main finding
As reported in the abstract
Complete remission without GC therapy
Step-down
50%
Observational data: associations, not effects.
Further findings
| Outcome | Values |
|---|---|
| Asthma or vasculitis exacerbations | Step-down 0 events |
Recurrence of sinonasal symptoms
- Treated with either increased mepolizumab dose or optimization of local therapy
Original publication
Step-down treatment with mepolizumab for eosinophilic granulomatosis with polyangiitis: a real-life single-centre study. Rheumatology (Oxford). Published 12 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →